This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Invitrogen
other brands :
NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience
product type :
antibody
product name :
CD152 (CTLA-4) Monoclonal Antibody (UC10-4B9), Biotin, eBioscience
catalog :
13-1522-82
quantity :
100 ug
price :
US 171.00
clonality :
monoclonal
host :
hamsters
conjugate :
biotin
clone name :
reactivity :
mouse
application :
flow cytometry
citations: 49
Reference
Yu L, Zhou B, Zhu Y, Li L, Zhong Y, Zhu L, et al. HSF1 promotes CD69+ Treg differentiation to inhibit colitis progression. Theranostics. 2023;13:1892-1905 pubmed publisher
Masle Farquhar E, Jeelall Y, White J, Bier J, Deenick E, Brink R, et al. CARD11 gain-of-function mutation drives cell-autonomous accumulation of PD-1+ ICOShigh activated T cells, T-follicular, T-regulatory and T-follicular regulatory cells. Front Immunol. 2023;14:1095257 pubmed publisher
Ma B, Kamle S, Akosman B, Khan H, Lee C, Lee C, et al. CHI3L1 enhances melanoma lung metastasis via regulation of T cell co-stimulators and CTLA-4/B7 axis. Front Immunol. 2022;13:1056397 pubmed publisher
Shen S, Li Y, Jin M, Fan D, Pan R, Lin A, et al. CD4+ CTLs Act as a Key Effector Population for Allograft Rejection of MSCs in a Donor MHC-II Dependent Manner in Injured Liver. Aging Dis. 2022;13:1919-1938 pubmed publisher
Kalim K, Yang J, Modur V, Nguyen P, Li Y, Zheng Y, et al. Graded RhoA GTPase Expression in Treg Cells Distinguishes Tumor Immunity From Autoimmunity. Front Immunol. 2021;12:726393 pubmed publisher
Lou Y, Wang J, Peng P, Wang S, Liu P, Xu L. Downregulated TNF-α Levels after Cryo-Thermal Therapy Drive Tregs Fragility to Promote Long-Term Antitumor Immunity. Int J Mol Sci. 2021;22: pubmed publisher
Skordos I, Demeyer A, Beyaert R. Analysis of T cells in mouse lymphoid tissue and blood with flow cytometry. STAR Protoc. 2021;2:100351 pubmed publisher
Ferrere G, Tidjani Alou M, Liu P, Goubet A, Fidelle M, Kepp O, et al. Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade. JCI Insight. 2021;6: pubmed publisher
Liu W, Dai E, Liu Z, Ma C, Guo Z, Bartlett D. In Situ Therapeutic Cancer Vaccination with an Oncolytic Virus Expressing Membrane-Tethered IL-2. Mol Ther Oncolytics. 2020;17:350-360 pubmed publisher
Lu Y, Kim N, Jiang Y, Zhang H, Zheng D, Zhu F, et al. Cambogin suppresses dextran sulphate sodium-induced colitis by enhancing Treg cell stability and function. Br J Pharmacol. 2018;175:1085-1099 pubmed publisher
Peer S, Baier G, Gruber T. Cblb-deficient T cells are less susceptible to PD-L1-mediated inhibition. Oncotarget. 2017;8:41841-41853 pubmed publisher
Zamarin D, Holmgaard R, Ricca J, Plitt T, Palese P, Sharma P, et al. Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity. Nat Commun. 2017;8:14340 pubmed publisher
Shi L, Fu T, Guan B, Chen J, Blando J, Allison J, et al. Interdependent IL-7 and IFN-? signalling in T-cell controls tumour eradication by combined ?-CTLA-4+?-PD-1 therapy. Nat Commun. 2016;7:12335 pubmed publisher
Tähtinen S, Kaikkonen S, Merisalo Soikkeli M, Grönberg Vähä Koskela S, Kanerva A, Parviainen S, et al. Favorable alteration of tumor microenvironment by immunomodulatory cytokines for efficient T-cell therapy in solid tumors. PLoS ONE. 2015;10:e0131242 pubmed publisher
González Mateo G, Fernández Míllara V, Bellón T, Liappas G, Ruiz Ortega M, López Cabrera M, et al. Paricalcitol reduces peritoneal fibrosis in mice through the activation of regulatory T cells and reduction in IL-17 production. PLoS ONE. 2014;9:e108477 pubmed publisher
Kim E, Gasper D, Lee S, Plisch E, Svaren J, Suresh M. Bach2 regulates homeostasis of Foxp3+ regulatory T cells and protects against fatal lung disease in mice. J Immunol. 2014;192:985-95 pubmed publisher
Graham J, Da Costa A, Lund J. Regulatory T cells shape the resident memory T cell response to virus infection in the tissues. J Immunol. 2014;192:683-90 pubmed publisher
Lee J, Jeon E, Kim N, Nam Y, Im K, Lim J, et al. The synergistic immunoregulatory effects of culture-expanded mesenchymal stromal cells and CD4(+)25(+)Foxp3+ regulatory T cells on skin allograft rejection. PLoS ONE. 2013;8:e70968 pubmed publisher
Huang H, Dawicki W, Lu M, Nayyar A, Zhang X, Gordon J. Regulatory dendritic cell expression of MHCII and IL-10 are jointly requisite for induction of tolerance in a murine model of OVA-asthma. Allergy. 2013;68:1126-35 pubmed publisher
Huang H, Ma Y, Dawicki W, Zhang X, Gordon J. Comparison of induced versus natural regulatory T cells of the same TCR specificity for induction of tolerance to an environmental antigen. J Immunol. 2013;191:1136-43 pubmed publisher
Rohlman D, Punj S, Pennington J, Bradford S, Kerkvliet N. Suppression of acute graft-versus-host response by TCDD is independent of the CTLA-4-IFN-?-IDO pathway. Toxicol Sci. 2013;135:81-90 pubmed publisher
Ehrentraut H, Clambey E, McNamee E, Brodsky K, Ehrentraut S, Poth J, et al. CD73+ regulatory T cells contribute to adenosine-mediated resolution of acute lung injury. FASEB J. 2013;27:2207-19 pubmed publisher
Mc Guire C, Wieghofer P, Elton L, Muylaert D, Prinz M, Beyaert R, et al. Paracaspase MALT1 deficiency protects mice from autoimmune-mediated demyelination. J Immunol. 2013;190:2896-903 pubmed publisher
Nakagomi D, Suzuki K, Hosokawa J, Kobayashi Y, Suto A, Takatori H, et al. Therapeutic potential of B and T lymphocyte attenuator expressed on CD8+ T cells for contact hypersensitivity. J Invest Dermatol. 2013;133:702-711 pubmed publisher
Park H, Kusnadi A, Lee E, Kim W, Cho B, Lee I, et al. Tumor-infiltrating regulatory T cells delineated by upregulation of PD-1 and inhibitory receptors. Cell Immunol. 2012;278:76-83 pubmed publisher
de Andrade Pereira B, Fraefel C, Hilbe M, Ackermann M, Dresch C. Transcriptional targeting of DCs with lentiviral vectors induces antigen-specific tolerance in a mouse model of multiple sclerosis. Gene Ther. 2013;20:556-66 pubmed publisher
Guo X, Jie Y, Ren D, Zeng H, Zhang Y, He Y, et al. In vitro-expanded CD4(+)CD25(high)Foxp3(+) regulatory T cells controls corneal allograft rejection. Hum Immunol. 2012;73:1061-7 pubmed publisher
Weiss R, Hessenberger M, Kitzmüller S, Bach D, Weinberger E, Krautgartner W, et al. Transcutaneous vaccination via laser microporation. J Control Release. 2012;162:391-9 pubmed publisher
Altin J, Goodnow C, Cook M. IL-10+ CTLA-4+ Th2 inhibitory cells form in a Foxp3-independent, IL-2-dependent manner from Th2 effectors during chronic inflammation. J Immunol. 2012;188:5478-88 pubmed publisher
Gu P, Gao J, D Souza C, Kowalczyk A, Chou K, Zhang L. Trogocytosis of CD80 and CD86 by induced regulatory T cells. Cell Mol Immunol. 2012;9:136-46 pubmed publisher
Tenorio E, Fernandez J, Castellanos C, Olguín J, Saavedra R. CD4+ Foxp3+ regulatory T cells mediate Toxoplasma gondii-induced T-cell suppression through an IL-2-related mechanism but independently of IL-10. Eur J Immunol. 2011;41:3529-41 pubmed publisher
Kastenmuller W, Gasteiger G, Subramanian N, Sparwasser T, Busch D, Belkaid Y, et al. Regulatory T cells selectively control CD8+ T cell effector pool size via IL-2 restriction. J Immunol. 2011;187:3186-97 pubmed publisher
Gaddis D, Michalek S, Katz J. TLR4 signaling via MyD88 and TRIF differentially shape the CD4+ T cell response to Porphyromonas gingivalis hemagglutinin B. J Immunol. 2011;186:5772-83 pubmed publisher
He C, Prevot N, Boitard C, Avner P, Rogner U. Inhibition of type 1 diabetes by upregulation of the circadian rhythm-related aryl hydrocarbon receptor nuclear translocator-like 2. Immunogenetics. 2010;62:585-92 pubmed publisher
Fulton R, Meyerholz D, Varga S. Foxp3+ CD4 regulatory T cells limit pulmonary immunopathology by modulating the CD8 T cell response during respiratory syncytial virus infection. J Immunol. 2010;185:2382-92 pubmed publisher
Sugita S, Horie S, Yamada Y, Mochizuki M. Inhibition of B-cell activation by retinal pigment epithelium. Invest Ophthalmol Vis Sci. 2010;51:5783-8 pubmed publisher
Teng L, Liu L, Su Y, Yuan X, Li J, Fu Q, et al. Suppression of alloimmunity in mice by regulatory T cells converted with conditioned media. J Surg Res. 2011;171:797-806 pubmed publisher
Zaiss M, Sarter K, Hess A, Engelke K, Böhm C, Nimmerjahn F, et al. Increased bone density and resistance to ovariectomy-induced bone loss in FoxP3-transgenic mice based on impaired osteoclast differentiation. Arthritis Rheum. 2010;62:2328-38 pubmed publisher
Sugita S, Horie S, Yamada Y, Keino H, Usui Y, Takeuchi M, et al. Suppression of bystander T helper 1 cells by iris pigment epithelium-inducing regulatory T cells via negative costimulatory signals. Invest Ophthalmol Vis Sci. 2010;51:2529-36 pubmed publisher
Pierau M, Engelmann S, Reinhold D, Lapp T, Schraven B, Bommhardt U. Protein kinase B/Akt signals impair Th17 differentiation and support natural regulatory T cell function and induced regulatory T cell formation. J Immunol. 2009;183:6124-34 pubmed publisher
Blache C, Adriouch S, Calbo S, Drouot L, Dulauroy S, Arnoult C, et al. Cutting edge: CD4-independent development of functional FoxP3+ regulatory T cells. J Immunol. 2009;183:4182-6 pubmed publisher
Liu Z, Kim J, Falo L, You Z. Tumor regulatory T cells potently abrogate antitumor immunity. J Immunol. 2009;182:6160-7 pubmed publisher
Kiesel J, Buchwald Z, Aurora R. Cross-presentation by osteoclasts induces FoxP3 in CD8+ T cells. J Immunol. 2009;182:5477-87 pubmed publisher
Saito K, Torii M, Ma N, Tsuchiya T, Wang L, Hori T, et al. Differential regulatory function of resting and preactivated allergen-specific CD4+ CD25+ regulatory T cells in Th2-type airway inflammation. J Immunol. 2008;181:6889-97 pubmed
Scumpia P, Delano M, Kelly Scumpia K, Weinstein J, Wynn J, Winfield R, et al. Treatment with GITR agonistic antibody corrects adaptive immune dysfunction in sepsis. Blood. 2007;110:3673-81 pubmed
Grigorian A, Lee S, Tian W, Chen I, Gao G, Mendelsohn R, et al. Control of T Cell-mediated autoimmunity by metabolite flux to N-glycan biosynthesis. J Biol Chem. 2007;282:20027-35 pubmed
Luo X, Tarbell K, Yang H, Pothoven K, Bailey S, Ding R, et al. Dendritic cells with TGF-beta1 differentiate naive CD4+CD25- T cells into islet-protective Foxp3+ regulatory T cells. Proc Natl Acad Sci U S A. 2007;104:2821-6 pubmed
Kapp J, Honjo K, Kapp L, Xu X, Cozier A, Bucy R. TCR transgenic CD8+ T cells activated in the presence of TGFbeta express FoxP3 and mediate linked suppression of primary immune responses and cardiac allograft rejection. Int Immunol. 2006;18:1549-62 pubmed
Zheng S, Meng L, Wang J, Watanabe M, Barr M, Cramer D, et al. Transfer of regulatory T cells generated ex vivo modifies graft rejection through induction of tolerogenic CD4+CD25+ cells in the recipient. Int Immunol. 2006;18:279-89 pubmed
product information
Product Type :
Antibody
Product Name :
CD152 (CTLA-4) Monoclonal Antibody (UC10-4B9), Biotin, eBioscience
Catalog # :
13-1522-82
Quantity :
100 ug
Price :
US 171.00
Clonality :
Monoclonal
Purity :
Affinity chromatography
Host :
Armenian Hamster
Reactivity :
Mouse
Applications :
Flow Cytometry: 1 ug/test
Species :
Mouse
Clone :
UC10-4B9
Isotype :
IgG
Storage :
4 C, store in dark, DO NOT FREEZE!
Description :
CTLA4 (Cytotoxic T-Lymphocyte Antigen 4) is a CD28-family receptor expressed on mainly CD4+ T cells. It binds the same ligands as CD28 (CD80 and CD86 on B cells and dendritic cells), but with higher affinity than CD28. However, in contrast to CD28 which enhances cell function when bound at the same time as the T cell receptor, CTLA4 inhbits the T cell and prevents it from functioning. Intracellular CTLA4 is also found in regulatory T cells and may be important to their function.
Format :
Liquid
Applications w/Dilutions :
Flow Cytometry: 1 ug/test
Aliases :
ALPS5; CD; CD152; CD152 antigen; CD152 isoform; CD152 protein; CD152 protein precursor; celiac disease 3; CELIAC3; Ctla4; CTLA-4; cytotoxic T lymphocyte associated antigen 4 short spliced form; cytotoxic T-lymphocyte associated protein 4; cytotoxic T-lymphocyte protein 4; cytotoxic T-lymphocyte protein 4 isoform CTLA4-TM; cytotoxic T-lymphocyte-associated antigen 4; cytotoxic T-lymphocyte-associated protein 4; cytotoxic T-lymphocyte-associated serine esterase-4; EGK_04712; GRD4; GSE; ICOS; IDDM12; insulin-dependent diabetes mellitus 12; ligand and transmembrane spliced cytotoxic T lymphocyte associated antigen 4; Ly-56; sCTLA4; soluble form; transmembrane form
company information
Invitrogen
Thermo Fisher Scientific
81 Wyman Street
Waltham, MA USA 02451
https://www.thermofisher.com
800-678-5599
headquarters: USA